ArticleGeroScience2026
Adipokines and satiety hormones and incidence of Alzheimer's disease and dementia in older adults: a nested case-control study.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Obesity is known to have an intricate relationship with the development of Alzheimer's disease and dementia (mid-life obesity increases risk, whereas late-life adiposity may also have an effect). In this context, adipokines and satiety signals are suggested to play a role in late life, but their association with the incidence of these outcomes remains unclear. Our study aimed to assess whether five selected plasma adipokines and satiety hormones (leptin, ghrelin, resistin, adipsin, and fibroblast growth factor-21) were associated with incident Alzheimer's disease and dementia in older adults at high cardiovascular risk in a nested case-control study within the PREDIMED trial (90 dementia cases [73 of which were Alzheimer's disease], 156 controls). Participants were at high cardiovascular disease risk but free from dementia at baseline. Associations with biomarkers were assessed using multivariable conditional logistic regression. Higher resistin levels were associated with higher incidence of Alzheimer's disease in the multivariable-adjusted model (per one SD increase: OR 1.56, 95% CI 1.02 to 2.38); additional adjustment for body mass index slightly attenuated the association (OR 1.52, 95% CI 0.99 to 2.34). Our findings should be replicated in larger prospective studies but suggest that, despite the complex association between anthropometric measures and the incidence of dementia, high levels of resistin were tentatively associated with greater odds of incident Alzheimer's disease in older adults at high cardiovascular risk.
Indexed as
Identifiers
42387181What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.